Egyptian liver library: An indexed database for liver disease evidence in Egypt

Alboraie, Mohamed; Youssef, Naglaa; Sherief, Ahmed Fouad; Afify, Shimaa; Wifi, Mohamed-Naguib; Omran, Dalia; Hafez, E. S. E.; Omar, Heba; Eltabbakh, Mohamed; Abd-Ellah, Mohamed F.; Badry, Mohamed El; Salaheldin, Mohamed; Ahmed, Yasmeen; Ali-Eldin, Zainab A.; Farid, Amir; Abdeen, Nermeen; Halwagy, Hesham El; Abdalgaber, Mohammad; Moaz, Inas; Ezzat, Sameera; Kassas, Mohamed El

doi:10.1016/j.ajg.2019.05.004

Cited by 16 publications

(12 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In general, there is no structured national research program for HCC in place. The same notice was reported on liver research in Egypt [106]. There are many important research topics in HCC are still untouched deeply.…”

Section: Clinical Trials Of Hccsupporting

confidence: 65%

“…Recently, Calderaro and colleagues proposed molecular and clinical features-based classification for HCC [105]. A recent systematic review identified 544 articles (16.2%) published in PubMed about HCC in Egypt [106]. In Egypt, some abnormalities in molecular pathways involved in HCC have been identified [107,108] but other abnormalities need to be identified on a large scale of HCC Egyptian patients using advanced technology.…”

Section: Hcc Researchmentioning

confidence: 99%

See 1 more Smart Citation

Hepatocellular Carcinoma (HCC) in Egypt: A comprehensive overview

Rashed

Kandeil

Mahmoud

et al. 2020

J Egypt Natl Canc Inst

Self Cite

197

163

View full text Add to dashboard Cite

Background: Worldwide, hepatocellular carcinoma (HCC) is a universal problem and its epidemiological data showed variation from place to place. Hepatocellular carcinoma (HCC) is the sixth and fourth common cancer in worldwide and Egypt, respectively. Egypt ranks the third and 15 th most populous country in Africa and worldwide, respectively. The aim of this review is to compare the status of HCC in Egypt to that in the worldwide from different issues; risk factors, screening and surveillance, diagnosis and treatment, prevention, as well as research strategy. Main body: The risk factors for HCC in Egypt are of great importance to be reported. The risk factor for HCC are either environmental-or host/genetic-related risk factors. In the last years, there is a tangible improvement of both screening and surveillance strategies of HCC in Egypt. The unprecedented national screening campaign launched by the end of 2018 is a mirror image of this improvement. While the improvement of the HCC prevention requires the governmental health administration to implement health policies. Although the diagnosis of Egyptian HCC patients follows the international guidelines but HCC treatment options are limited in terms of cost. In addition, there are limited Egyptian reports about HCC survival and relapse. Both basic and clinical HCC research in Egypt are still limited compared to worldwide. Short conclusion: Deep analysis and understanding of factors affecting HCC burden variation worldwide help in customization of efforts exerted to face HCC in different countries especially large country like Egypt. Overall, the presence of a research strategy to fight HCC in Egyptian patients will help in the optimum allocation of available resources to reduce the numbers of HCC cases and deaths and to improve the quality of life.

show abstract

Section: Clinical Trials Of Hccsupporting

confidence: 65%

Section: Hcc Researchmentioning

confidence: 99%

Hepatocellular Carcinoma (HCC) in Egypt: A comprehensive overview

Rashed

Kandeil

Mahmoud

et al. 2020

J Egypt Natl Canc Inst

Self Cite

197

163

View full text Add to dashboard Cite

show abstract

“…Similarly, while many countries such as Egypt have very effective action plans for viral hepatitis, there are no similar policies to combat the growing burden of MAFLD 54 . In addition research outputs related to MAFLD have been disproportionally low 55 . The consequences are that it undermines progress towards improvements in human capital and the goal of universal health coverage.…”

Section: Historical Perspective On Fatty Liver Nomenclaturementioning

confidence: 99%

What's in a name? Renaming ‘NAFLD’ to ‘MAFLD’

Fouad

Waked

Bollipo

et al. 2020

Liver International

248

185

View full text Add to dashboard Cite

In medicine, language matters and the words used to name and describe a disease can have a profound impact on patients and their families. Over the last two decades, many criticisms have been voiced about the nomenclature and definition of non-alcoholic fatty liver disease (NAFLD) in regards not only to the prominent role that alcohol plays in the definition but also on the negative impacts of the nomenclature including trivialization, stigmatization and less consideration of the disease in health policy. Recently, a consensus of international experts proposed that the disease acronym be changed from NAFLD to metabolic (dysfunction) associated fatty liver disease or 'MAFLD'. This change goes far beyond a mere semantic revision and may be the first step that catalyses the process to better conceptualize the disease for health promotion, patient orientation, case identification, ongoing clinical trials and for health services delivery. Here we review the history of, and definitions of MAFLD in the context of advancing our understanding of the pathogenesis of the disease. We also address the reasons, signals, promises, challenges and the way going forward from the name change from various stakeholder perspectives. K E Y W O R D S MAFLD, metabolic, nomenclature | 1255 FOUAD et Al.

show abstract

“…19 In Egypt, HCC is a very prevalent source of cancer incidence and mortality among men. 20 The high incidence of HCC in Egypt is clearly attributed to high prevalence of chronic viral infection of the liver especially HCV. 21 Due to the functional derangements and defective capacity of regeneration in the setting of cirrhosis, patients with liver cirrhotic are more vulnerable to postoperative complications, including mortality, after partial liver resection.…”

Section: Introductionmentioning

confidence: 99%

Cirrhosis aggravates the ninety-day mortality after liver resection for hepatocellular carcinoma

Abdelhameed

El‐Badry

2019

Int Surg J

View full text Add to dashboard Cite

Background: Ninety-day postoperative mortality (90-D POM) measures accurately the liver resection-related mortality. In cirrhotic patients, reporting post-hepatectomy-related death only as in-hospital or thirty-day postoperative mortality (30-D POM) may underestimate cirrhosis-related death after liver resection.Methods: Medical records of adult cirrhotic (cirrhosis group) and matched non-cirrhotic (control group) patients, who underwent elective liver resection at Sohag University Hospital (April 2014- March 2018), were analyzed. The 90-D POM versus in-hospital mortality and 30-D POM were compared in both groups.Results: Forty-six patients (23 per group) were eligible for the study. Liver resection was carried out in all cirrhosis group patients for hepatocellular carcinoma (HCC). In the control group, liver resection was indicated for colorectal metastasis (13), benign masses (7) and intrahepatic cholangiocarcinoma (3). Compared with the control group, cirrhotic patients exhibited significantly higher complication rates (p<0.05), prolonged hospital stays (p<0.05), increased postoperative levels of serum bilirubin and reduced prothrombin concentration (p<0.05). In the control group, in-hospital mortality and 30-D POM were zero while 90-D POM was 4%. In the cirrhosis group, the in-hospital mortality and 30-D POM were identical (8.7%), however the 90-D POM was significantly higher and almost doubled (17%). Conclusion: Liver cirrhosis triggers significant mortality that may extend for ninety days postoperatively. In cirrhotic patients, post-hepatectomy death should be reported as 90-D POM rather than the obviously misleading in-hospital mortality or 30-D POM.

show abstract

Egyptian liver library: An indexed database for liver disease evidence in Egypt

Cited by 16 publications

References 8 publications

Hepatocellular Carcinoma (HCC) in Egypt: A comprehensive overview

Hepatocellular Carcinoma (HCC) in Egypt: A comprehensive overview

What's in a name? Renaming ‘NAFLD’ to ‘MAFLD’

Cirrhosis aggravates the ninety-day mortality after liver resection for hepatocellular carcinoma

Contact Info

Product

Resources

About